TMPRSS2 and prostate carcinoma: In a study of 9280 COVID-19 patients from 68 hospitals in northeastern Italy, the researchers found that patients with prostate cancer and patients not treated with androgen deprivation were more susceptible to SARS-CoV-2 infection than patients treated with androgen deprivation, which would reduce the expression of TMPRSS2 [34].